Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
06 2019
Historique:
received: 10 07 2018
revised: 17 12 2018
accepted: 02 01 2019
pubmed: 28 1 2019
medline: 2 12 2020
entrez: 28 1 2019
Statut: ppublish

Résumé

In liver transplantation, organ shortage leads to the use of marginal grafts that are more susceptible to ischemia-reperfusion (IR) injury. We identified nucleotide-binding oligomerization domain 1 (NOD1) as an important modulator of polymorphonuclear neutrophil (PMN)-induced liver injury, which occurs in IR. Herein, we aimed to elucidate the role of NOD1 in IR injury, particularly focusing on its effects on the endothelium and hepatocytes. Nod1 WT and KO mice were treated with NOD1 agonists and subjected to liver IR. Expression of adhesion molecules was analyzed in total liver, isolated hepatocytes and endothelial cells. Interactions between PMNs and hepatocytes were studied in an ex vivo co-culture model using electron microscopy and lactate dehydrogenase levels. We generated NOD1 antagonist-loaded nanoparticles (np ALINO). NOD1 agonist treatment increased liver injury, PMN tissue infiltration and upregulated ICAM-1 and VCAM-1 expression 20 hours after reperfusion. NOD1 agonist treatment without IR increased expression of adhesion molecules (ICAM-1, VCAM-1) in total liver and more particularly in WT hepatocytes, but not in Nod1 KO hepatocytes. This induction is dependent of p38 and ERK signaling pathways. Compared to untreated hepatocytes, a NOD1 agonist markedly increased hepatocyte lysis in co-culture with PMNs as shown by the increase of lactate dehydrogenase in supernatants. Interaction between hepatocytes and PMNs was confirmed by electron microscopy. In a mouse model of liver IR, treatment with np ALINO significantly reduced the area of necrosis, aminotransferase levels and ICAM-1 expression. NOD1 regulates liver IR injury through induction of adhesion molecules and modulation of hepatocyte-PMN interactions. NOD1 antagonist-loaded nanoparticles reduced liver IR injury and provide a potential approach to prevent IR, especially in the context of liver transplantation. Nucleotide-binding oligomerization domain 1 (NOD1) is as an important modulator of polymorphonuclear neutrophil (PMN)-induced liver injury, which occurs in ischemia-reperfusion. Here, we show that the NOD1 pathway targets liver adhesion molecule expression on the endothelium and on hepatocytes through p38 and ERK signaling pathways. The early increase of adhesion molecule expression after reperfusion emphasizes the importance of adhesion molecules in liver injury. In this study we generated nanoparticles loaded with NOD1 antagonist. These nanoparticles reduced liver necrosis by reducing PMN liver infiltration and adhesion molecule expression.

Sections du résumé

BACKGROUND & AIMS
In liver transplantation, organ shortage leads to the use of marginal grafts that are more susceptible to ischemia-reperfusion (IR) injury. We identified nucleotide-binding oligomerization domain 1 (NOD1) as an important modulator of polymorphonuclear neutrophil (PMN)-induced liver injury, which occurs in IR. Herein, we aimed to elucidate the role of NOD1 in IR injury, particularly focusing on its effects on the endothelium and hepatocytes.
METHOD
Nod1 WT and KO mice were treated with NOD1 agonists and subjected to liver IR. Expression of adhesion molecules was analyzed in total liver, isolated hepatocytes and endothelial cells. Interactions between PMNs and hepatocytes were studied in an ex vivo co-culture model using electron microscopy and lactate dehydrogenase levels. We generated NOD1 antagonist-loaded nanoparticles (np ALINO).
RESULTS
NOD1 agonist treatment increased liver injury, PMN tissue infiltration and upregulated ICAM-1 and VCAM-1 expression 20 hours after reperfusion. NOD1 agonist treatment without IR increased expression of adhesion molecules (ICAM-1, VCAM-1) in total liver and more particularly in WT hepatocytes, but not in Nod1 KO hepatocytes. This induction is dependent of p38 and ERK signaling pathways. Compared to untreated hepatocytes, a NOD1 agonist markedly increased hepatocyte lysis in co-culture with PMNs as shown by the increase of lactate dehydrogenase in supernatants. Interaction between hepatocytes and PMNs was confirmed by electron microscopy. In a mouse model of liver IR, treatment with np ALINO significantly reduced the area of necrosis, aminotransferase levels and ICAM-1 expression.
CONCLUSION
NOD1 regulates liver IR injury through induction of adhesion molecules and modulation of hepatocyte-PMN interactions. NOD1 antagonist-loaded nanoparticles reduced liver IR injury and provide a potential approach to prevent IR, especially in the context of liver transplantation.
LAY SUMMARY
Nucleotide-binding oligomerization domain 1 (NOD1) is as an important modulator of polymorphonuclear neutrophil (PMN)-induced liver injury, which occurs in ischemia-reperfusion. Here, we show that the NOD1 pathway targets liver adhesion molecule expression on the endothelium and on hepatocytes through p38 and ERK signaling pathways. The early increase of adhesion molecule expression after reperfusion emphasizes the importance of adhesion molecules in liver injury. In this study we generated nanoparticles loaded with NOD1 antagonist. These nanoparticles reduced liver necrosis by reducing PMN liver infiltration and adhesion molecule expression.

Identifiants

pubmed: 30685324
pii: S0168-8278(19)30033-9
doi: 10.1016/j.jhep.2019.01.019
pii:
doi:

Substances chimiques

NOD1 protein, human 0
Nod1 Signaling Adaptor Protein 0
Vascular Cell Adhesion Molecule-1 0
Intercellular Adhesion Molecule-1 126547-89-5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1159-1169

Subventions

Organisme : NIAAA NIH HHS
ID : U01 AA021908
Pays : United States

Informations de copyright

Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Auteurs

Guillaume Lassailly (G)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France. Electronic address: guillaume.lassailly@chru-lille.fr.

Mohamed Bou Saleh (M)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.

Natascha Leleu-Chavain (N)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Institut de Chimie Pharmaceutique de Lille, Faculté de Pharmacie, Univ Lille, F-59000 Lille, France.

Massih Ningarhari (M)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France.

Emilie Gantier (E)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.

Rodolphe Carpentier (R)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.

Florent Artru (F)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France.

Viviane Gnemmi (V)

Service d'anatomopathologie, CHU Lille, F-59000 Lille, France.

Benjamin Bertin (B)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.

Patrice Maboudou (P)

UF 8832 - Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, CHRU de Lille, F-59000 Lille, France.

Didier Betbeder (D)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Université d'artois, F-62300 Lens, France.

Céline Gheeraert (C)

U1011 - EGID, Univ. Lille, Inserm, Institut Pasteur de Lille, F-59000 Lille, France.

François Maggiotto (F)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.

Sébastien Dharancy (S)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France.

Philippe Mathurin (P)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France.

Alexandre Louvet (A)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, CHU Lille, F-59000 Lille, France.

Laurent Dubuquoy (L)

LIRIC - Lille Inflammation Research International Center - U995, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France. Electronic address: laurent.dubuquoy@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH